Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Heart failure is an epidemiologically relevant disease because of the aging population and widespread lifestyles that promote it. In addition to the acute event, it is possible for the disease to become chronic with periodic flare-ups. It is essential to study pathology from a diagnostic and prognostic point of view and to identify parameters for effective monitoring. In addition, heart failure is associated with multiple comorbidities, including cognitive impairment, which is monitored clinically but not through specific biomarkers in these patients. The purpose of this review is to gather the most recent scientific evidence on a few possible biomarkers previously identified for monitoring heart failure and associated cognitive impairment.

Methods: We surveyed studies inherent to a set of previously identified markers, evaluating English-language articles from the past five years conducted in adult heart failure patient populations. We used the databases PubMed, Web of Sciences, and Cochrane Library for search studies, and we considered articles published in journals with an impact factor greater than five in the publication year.

Results: Among the biomarkers evaluated, a concordant indication for serial measurements for heart failure monitoring emerged only for interleukin-6. For the other markers, there is still little evidence available, which is interesting but sometimes conflicting. Interesting studies have also emerged for biomarkers of cognitive decline assessed in patients with heart failure, confirming the hypotheses of the increasingly studied heart-brain correlation.

Conclusion: Certainly, further studies in large populations are needed to identify effective biomarkers for monitoring heart failure and associated cognitive impairment.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10886491PMC
http://dx.doi.org/10.3390/biom14020185DOI Listing

Publication Analysis

Top Keywords

heart failure
32
monitoring heart
12
cognitive impairment
12
failure associated
12
heart
8
failure
8
associated cognitive
8
monitoring
5
cognitive
5
biomarkers
5

Similar Publications

Aims: There is a lack of data from randomized clinical trials comparing treatment outcomes between conduction system pacing (CSP) modalities and biventricular pacing (BVP) in symptomatic patients with refractory atrial fibrillation (AF) scheduled for atrioventricular node ablation (AVNA). The CONDUCT-AF investigates whether CSP is non-inferior to BVP in improving left ventricular ejection fraction (LVEF) and clinical outcomes in heart failure (HF) patients with symptomatic AF undergoing AVNA.

Methods: This study is an investigator-initiated, prospective, randomized, multicentre clinical trial conducted across 10 European centres, enrolling 82 patients with symptomatic AF, HF with reduced LVEF, and narrow QRS.

View Article and Find Full Text PDF

Importance: The cardiovascular benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may vary by body mass index (BMI), but evidence on BMI-specific outcomes remains limited.

Objective: To investigate the associations of GLP-1 RA use with cardiovascular and kidney outcomes across BMI categories in patients with type 2 diabetes.

Design, Setting, And Participants: This retrospective cohort study used the Chang Gung Research Database, a clinical dataset covering multiple hospitals in Taiwan.

View Article and Find Full Text PDF

Purpose Of Review: Symptom relief is now recognized as the primary remit of percutaneous coronary intervention (PCI) in patients with stable coronary artery disease. The relationship between the nature of angina symptoms and the likelihood of successful symptom relief from PCI had not been systematically studied until recently.

Recent Findings: The ORBITA-2 symptom-stratified analysis found that while the severity and nature of symptoms were poorly associated with the severity of coronary disease, the nature of the symptoms powerfully predicted the efficacy of PCI in relieving angina.

View Article and Find Full Text PDF

Arterial Stiffness in HFpEF: From Clinical Insight to Bedside Action.

Cardiol Rev

September 2025

From the Department of General Medicine, J.S.S. Medical College, JSS Academy of Higher Education and Research, Mysuru, India.

Heart failure with preserved ejection fraction (HFpEF) accounts for nearly half of all heart failure cases and is increasing in prevalence due to aging populations and comorbidities such as hypertension and diabetes. While echocardiography remains the diagnostic cornerstone, many patients with preserved ejection fraction present with nonspecific symptoms and ambiguous diastolic indices, leading to diagnostic uncertainty and therapeutic delay. Arterial stiffness-quantified by pulse wave velocity, augmentation index, and cardio-ankle vascular index)-is emerging as a key contributor to HFpEF pathophysiology.

View Article and Find Full Text PDF